stoxline Quote Chart Rank Option Currency Glossary
Veru Inc. (VERU)
1.01  0.055 (5.75%)    12-01 16:00
Open: 0.9212
High: 1.01
Volume: 560,357
Pre. Close: 0.9551
Low: 0.9212
Market Cap: 91(M)
Technical analysis
2023-12-01 4:23:23 PM
Short term     
Mid term     
Targets 6-month :  1.33 1-year :  1.55
Resists First :  1.13 Second :  1.33
Pivot price 0.98
Supports First :  0.94 Second :  0.82
MAs MA(5) :  0.96 MA(20) :  0.98
MA(100) :  1 MA(250) :  2.12
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  30.7 D(3) :  27.1
RSI RSI(14): 54.4
52-week High :  6.57 Low :  0.66
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VERU ] has closed below upper band by 34.9%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.01 - 1.02 1.02 - 1.02
Low: 0.91 - 0.92 0.92 - 0.92
Close: 1 - 1.01 1.01 - 1.02
Company Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Headline News

Thu, 30 Nov 2023
Do Traders Think Veru Inc (VERU) Can Turn Around Thursday? - InvestorsObserver

Mon, 20 Nov 2023
Should You Buy Veru Inc (VERU) Stock After it Has Gained 6.38% in a Week? - InvestorsObserver

Sun, 19 Nov 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - PR Newswire

Thu, 16 Nov 2023
Amidst increasing losses, Investors bid up Veru (NASDAQ:VERU) 17% this past week - Simply Wall St

Wed, 08 Nov 2023
Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue ... - Nasdaq

Wed, 20 Sep 2023
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 90 (M)
Shares Float 70 (M)
Held by Insiders 22.9 (%)
Held by Institutions 36 (%)
Shares Short 14,270 (K)
Shares Short P.Month 13,190 (K)
Stock Financials
EPS -1.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.23
Profit Margin 0 %
Operating Margin -377.1 %
Return on Assets (ttm) -72.1 %
Return on Equity (ttm) -178.4 %
Qtrly Rev. Growth -65.2 %
Gross Profit (p.s.) 0.33
Sales Per Share 0.16
EBITDA (p.s.) -1.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -99 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -0.75
PEG Ratio -0.1
Price to Book value 4.2
Price to Sales 6.07
Price to Cash Flow -0.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android